the United States. It is not controlled internationally under the Convention on Psychotropic Substances or the Single Convention on Narcotic Drugs. The WHO Expert Committee on Drug Dependence reviewed ketamine at its 34th, 35th, and 36th meetings. Ketamine is controlled in schedule III of the CSA in the United States, and additional controls may be necessary to fulfill U.S. obligations if ketamine is controlled under Schedule I of the Psychotropic Convention. FDA, on behalf of the Secretary of HHS, invites interested persons to submit comments on the notifications from the United Nations concerning these drug substances. FDA, in cooperation with the National Institute on Drug Abuse, will consider the comments on behalf of HHS in evaluating the WHO scheduling recommendations. Then, under section 210(d)(2)(B) of the CSA, HHS will recommend to the Secretary of State what position the United States should take when voting on the recommendations for control of substances under the Psychotropic Convention at the CND meeting in March 2015.

Comments regarding the WHO recommendations for control of AH-7921 under the 1961 Single Convention will also be forwarded to the relevant Agencies for consideration in developing the U.S. position regarding narcotic substances at the CND meeting.

IV. Submission of Comments and Opportunity for Public Meeting

Interested persons may submit either electronic comments regarding this document to http://www.regulations.gov or written comments to the Division of Dockets Management (see ADDRESSES). It is only necessary to send one set of comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday, and will be posted to the docket at http://www.regulations.gov.

FDA does not presently plan to hold a public meeting. If any person believes that, in addition to written comments, a public meeting would contribute to the development of the U.S. position on the substances to be considered for control under the Psychotropic Convention, a request for a public meeting and the reasons for such a request should be sent to James R. Hunter (see FOR FURTHER INFORMATION CONTACT) on or before February 6, 2015.

The short time period for the submission of comments and requests for a public meeting is needed to ensure that HHS may, in a timely fashion, carry out the required action and be responsive to the United Nations.

Dated: January 21, 2015.

Leslie Kux,
Associate Commissioner for Policy.

[FR Doc. 2015–01408 Filed 1–26–15; 8:45 am]
II. Goals and Objectives

- To provide a forum for open discussion between industry, academia, other stakeholders, and FDA around proposed changes to the Food-Effect Guidance.
- To seek feedback from industry, academia, and other stakeholders on FDA’s proposals and to seek any additional input that will benefit decision making on a guidance revision on the topic.

Dated: January 21, 2015.

Leslie Kux,
Associate Commissioner for Policy.

AGENCY: Food and Drug Administration.

This notice is being published in the Federal Register to announce a public conference entitled “Leadership in a Global Supply Chain: Nobel Prize-Based Alignment—Establishing Good Supply Practices—Regulatory Agency Perspective on Innovation Act Implementation.”

The conference will be held on March 25, 2015, from 8:30 a.m. to 5 p.m.; March 26, 2015, from 8:30 a.m. to 5 p.m.; and March 27, 2015, from 8:30 a.m. to 12:45 p.m.

Location: The public conference will be held on the campus of Xavier University, 3800 Victory Pkwy., Cincinnati, OH 45207–5471, 513–745–3073, email: steven.eastham@fda.hhs.gov.

Registration: There is a registration fee. The conference registration fees cover the cost of the presentations, training materials, receptions, breakfasts, lunches, and dinners for the 2 1/2 days of the conference. There will be on-site registration. The cost of registration is as follows:

<table>
<thead>
<tr>
<th>Attendee type</th>
<th>Early rate (on or before 1/24/15)</th>
<th>Advanced rate (1/25/15 to 2/24/15)</th>
<th>Standard rate (after 2/24/15)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Industry</td>
<td>$1,295</td>
<td>$1,695</td>
<td>$1,895</td>
</tr>
<tr>
<td>Small Business (&lt;100 employees)</td>
<td>995</td>
<td>1,195</td>
<td>1,295</td>
</tr>
<tr>
<td>Startup Manufacturer</td>
<td></td>
<td>200</td>
<td>250</td>
</tr>
<tr>
<td>Academic</td>
<td></td>
<td>200</td>
<td>250</td>
</tr>
<tr>
<td>Media</td>
<td>Free</td>
<td>Free</td>
<td>Free</td>
</tr>
<tr>
<td>Government</td>
<td>Free</td>
<td>Free</td>
<td>Free</td>
</tr>
</tbody>
</table>

The fourth registration from the same company is free—all four attendees must register at the same time.

The following forms of payment will be accepted: American Express, Visa, Mastercard, and company checks.

To register online for the public conference, please visit the "Registration" link on the conference Web site at http://www.XavierPharmaLink.com. FDA has verified the Web site address, but is not responsible for subsequent changes to the Web site after this document publishes in the Federal Register.

To register by mail, please send your name, title, firm name, address, telephone and fax numbers, email, and payment information for the fee to Xavier University, Attention: Mason Rick, 3800 Victory Pkwy., Cincinnati, OH 45207–5471. An email will be sent confirming your registration.

Attendees are responsible for their own accommodations. The conference headquarters hotel is the Downtown Cincinnati Hilton Netherlands Plaza, 35 West 5th Street, Cincinnati, OH 45202, 513–421–9100. To make reservations online, please visit the “Venue & Logistics” link at http://www.XavierPharmaLink.com. The hotel is expected to sellout during this timeframe, so early reservation in the conference room-block is encouraged.

If you need special accommodations due to a disability, please contact Marla Phillips (see Contact Persons) at least 7 days in advance of the conference.

SUPPLEMENTARY INFORMATION: The public conference helps fulfill the Department of Health and Human Services’ and FDA’s important mission to protect the public health. The conference will engage those involved in FDA-regulated global supply chain quality and management through the following topics:

- Major Changes at FDA Affecting You
- FDA-Driven Initiatives through Food and Drug Administration Safety and Innovation Act Implementation
- Held at the Border? Understand Why
- Toyota Production System—Cultural Requirements
- Barriers to Quality and Supply Chain Excellence
- Establishing Good Supply Practices
- Medicines and Healthcare Products Regulatory Agency Perspective on Global Supply Chain Challenges
- Systematic Approach to Managing Your Global Supply Chain
- Deep Dive Lunch Session—Clinically Relevant Metrics
- Deep Dive Lunch Session—Data Integrity: How To Verify You Are Okay
- Deep Dive Lunch Session—Integrity of Supply Workshop
- Nobel Prize-Based Alignment Optimization